Edwards Lifesciences quarterly revenue rises 10.5% to $1.72 billion
Edwards Lifesciences' revenue growth is slowing. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Nov 4, 2026.
Snapshot
Edwards Lifesciences' revenue growth is slowing: revenue rose 10.5% to $1.72 billion in the quarter ended September 30, 2026, from $1.55 billion a year earlier, after 13.6% year over year growth the quarter before.
- Independent Research
Market Data
| Company | 1D % | Price |
|---|---|---|
| ($EW) | ▲ +1.46% | 100.82 |
as of 16:00 ET · Realtime derived data
What We Know
Revenue for the quarter ended September 30, 2026 was $1.72 billion, versus $1.55 billion in the same quarter a year earlier, up 10.5%. Diluted earnings per share was $0.53, up from $0.50.
Quarterly revenue by fiscal quarter end, oldest first: Dec 2024: $1.39 billion; Mar 2025: $1.41 billion; Jun 2025: $1.53 billion; Sep 2025: $1.55 billion; Dec 2025: $1.57 billion; Mar 2026: $1.65 billion; Jun 2026: $1.74 billion; Sep 2026: $1.72 billion.
Octans View
Year over year revenue change by quarter, computed from the filed figures: Dec 2025 up 13.3%; Mar 2026 up 16.7%; Jun 2026 up 13.6%; Sep 2026 up 10.5%. On those figures, Edwards Lifesciences' revenue growth is slowing. That read compares the latest two year over year growth rates and nothing else.
Bear Case · Room for Disagreement
This brief covers reported revenue and diluted earnings per share only. It does not cover guidance, margins, segment results, cash flow or the earnings call, and it makes no forecast. Revenue is the total on the release line we matched; a company's own adjusted measures can differ.
Method and source. Octans Research matched the revenue line in the earnings release (Exhibit 99.1) to the year ago quarter the company reported in its own XBRL financial data; the two must agree before anything is published. The quarterly history comes from the same XBRL data. The text is generated from those verified figures by a fixed template; no model wrote it.
Chart
Sources
- [1]SEC EDGAR — Edwards Lifesciences earnings release for the quarter ended September 30, 2026 (Exhibit 99.1), filed Nov 4, 2026
- [2]SEC EDGAR — Edwards Lifesciences XBRL financial data (company facts)
These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.
$1.72B
More on $EW
4 reports
CF Industries quarterly revenue rises 12.1% to $1.86 billion
CF Industries' revenue growth is slowing. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Nov 4, 2026.
CF Industries quarterly revenue rises 12.1% to $1.86 billion
CF Industries' revenue growth is slowing. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Nov 4, 2026.
Amcor quarterly revenue rises 6.7% to $6.13 billion
Amcor's revenue growth has more than halved. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Nov 4, 2026.
Corpay quarterly revenue rises 17.9% to $1.38 billion
Corpay's revenue growth is slowing. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Nov 4, 2026.